The fiscal fourth quarter, operating income, as a percentage of operating revenue was 1.73 percent compared to 1.86 percent for the prior year period.

Operating income advanced 68 percent to $94.8 million in the fourth quarter of fiscal year 2001 from $56.4 million for the same quarter last year. For percent a year ago. For the full fiscal year, the ratio declined 29 basis points to 2.45 percent compared to 2.74 percent last year.

Total operating expenses as a percentage of operating revenue declined 30 basis points to 2.42 percent in the fourth quarter of fiscal 2001 from 2.72 percent a year ago. The gross margin decrease was due to customer mix, a competitive environment, and the inventory write-downs in the quarter of $5.6 million or 10 basis points, primarily related to the cosmetic distribution subsidiary.

For the fiscal year, gross margin was 4.19 percent versus 4.48 percent in the prior year. For the fourth quarter of fiscal 2001, gross margin as a percentage of operating revenue was 4.15 percent versus 4.58 percent in the prior year's last quarter. The gross margin decrease was due to customer mix, a competitive environment, and the inventory write-downs in the quarter of $5.6 million or 10 basis points, primarily related to the cosmetic distribution subsidiary.

For the fiscal year, gross margin was 4.19 percent versus 4.48 percent in the prior year.

Total operating expenses as a percentage of operating revenue declined 30 basis points to 2.42 percent in the fourth quarter of fiscal 2001 from 2.72 percent a year ago. For the full fiscal year, the ratio declined 29 basis points to 2.45 percent compared to 2.74 percent last year.

Operating income advanced 68 percent to $94.8 million in the fourth quarter of fiscal year 2001 from $56.4 million for the same quarter last year. For the fiscal fourth quarter, operating income, as a percentage of operating revenue was 1.73 percent compared to 1.86 percent for the prior year period.
Operating margin was down 13 basis points, due primarily to the inclusion of the corporate and administrative costs of Bergen in the quarter.

"As the leader in the Health Systems, Alternate Site, Community Pharmacy, and Regional Drugstore Chain customer groups, AmerisourceBergen Drug Company has a broad, diversified customer base that continues to provide the opportunity to grow our drug company revenue," said Kurt Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "The Drug Company continued to show strong forward momentum as it expands current accounts and adds new business.

"Growth also continues to be strong in the Specialty Group as it builds on its strong positions in oncology, blood plasma and vaccine distribution," he said.

Commenting on integration activities, Hilzinger said, "We continue to move forward in an aggressive, but measured manner. Our integration plans reflect our commitment to consolidate seven facilities in fiscal year 2002, beginning with two smaller distribution centers next month.

"We are developing the information systems to effectively implement the other distribution center consolidations, and we are consolidating our procurement activities to improve our inventory productivity and vendor margin contribution."

PharMerica's revenue and operating income for the reported fourth quarter and the fiscal year 2001 represents the month of September. Revenues and operating income for each of the quarter and fiscal year were $116.7 million and $6.5 million, respectively.

On a pro forma basis, fiscal 2001 fourth quarter revenue increased 5 percent to $338.1 million from $323.5 million in the same period last year. Revenues for the year increased 6 percent to $1.35 billion.

"PharMerica continues to improve its performance through a combination of disciplined growth and expense control," said Hilzinger. "Asset management has improved as illustrated by reductions in gross days-sales-outstanding (DSO), which were 65 in the quarter, down from 83 in the same quarter last year. Net DSOs dropped from 55 in the prior year's fourth quarter to 47 in the current fourth quarter."

Looking Ahead

"In fiscal 2002, we expect continued strong performance for AmerisourceBergen with revenue growth of 15 percent to 17 percent, ROCC in excess of 20 percent, and earnings per share growth of 20 percent, excluding the impact of merger-related special items and elimination of goodwill amortization," said Yost. "The merger is complete, the integration is well under way, and we feel confident in our ability to drive shareholder value over the long term."

Conference Call

The Company will host a conference call to discuss the results at 11:00 am Eastern Standard Time on November 8, 2001. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; Neil F. Dimick, Executive Vice President & Chief Financial Officer.

To access the live conference call via telephone:

Dial in: 800/230-1092 from inside the U.S. no access code required
or 612/332-0107 from outside the U.S. no access code required.
To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

A replay of the telephone call and webcast will be available from 2:30 pm November 8, 2001 until 11:59 pm November 15, 2001.

To access the replay via telephone:

Dial in: 800/475-6701 from within the U.S., access code: 607336
320/365-3844 from outside the U.S., access code: 607336
To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, independent community pharmacies, and regional chains.

The Company is also a leader in the institutional pharmacy marketplace. With approximately $35 billion in annualized operating revenues, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

Forward-Looking Statements
This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.

Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmeriSource's and Bergen Brunswig's filings with the Securities and Exchange Commission, including each of their Annual Reports on Form 10-K for fiscal 2000, their most recent quarterly reports on Form 10-Q, and their joint proxy statement-prospectus dated August 1, 2001.

AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

### AMERISOURCEBERGEN CORPORATION

#### FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

<table>
<thead>
<tr>
<th>Three Months Ended</th>
<th>% of</th>
<th>Three Months Ended</th>
<th>% of</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 30, Operating</td>
<td>Revenue</td>
<td>September 30, 2000</td>
<td>Revenue</td>
</tr>
<tr>
<td>2001</td>
<td>100.00%</td>
<td>2000</td>
<td>100.00%</td>
</tr>
<tr>
<td>82%</td>
<td>5,516,347</td>
<td>3,027,776</td>
<td></td>
</tr>
<tr>
<td>Bulk deliveries to customer warehouses</td>
<td>367,884</td>
<td>3,954</td>
<td></td>
</tr>
<tr>
<td>Total revenue</td>
<td>5,884,231</td>
<td>3,031,730</td>
<td></td>
</tr>
<tr>
<td>Cost of goods sold</td>
<td>5,617,654</td>
<td>2,893,112</td>
<td></td>
</tr>
<tr>
<td>Gross profit</td>
<td>266,577</td>
<td>4.83%</td>
<td>138,618</td>
</tr>
<tr>
<td>Operating expenses:</td>
<td>Distribution, selling and administrative</td>
<td>156,103</td>
<td>2.83%</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>9,209</td>
<td>0.17%</td>
<td>4,283</td>
</tr>
<tr>
<td>Facility consolidations and employee severance</td>
<td>10,912</td>
<td>0.20%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Merger costs</td>
<td>12,206</td>
<td>0.22%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Environmental remediation</td>
<td>(2,716)</td>
<td>-0.05%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Operating income</td>
<td>80,863</td>
<td>1.47%</td>
<td>56,377</td>
</tr>
<tr>
<td>Equity in losses of affiliates and other</td>
<td>6,285</td>
<td>0.11%</td>
<td>568</td>
</tr>
<tr>
<td>Interest expense</td>
<td>15,647</td>
<td>0.28%</td>
<td>10,654</td>
</tr>
<tr>
<td>Income before taxes and distributions on preferred securities of</td>
<td>62,331</td>
<td>1.14%</td>
<td>50,151</td>
</tr>
</tbody>
</table>

---

---
subsidiary trust               58,931     1.07%       45,155      1.49%     31%
Taxes on income      23,042     0.42%       17,159      0.57%     34%

----------             ----------
Income before
distributions
on preferred
securities
of subsidiary
trust               35,889     0.65%       27,996      0.92%     28%
Distributions
on preferred
securities of
subsidiary
trust, net of
income tax
benefit of $871      1,306     0.02%            -      0.00%     N/A

----------             ----------
Net income          $34,583     0.63%      $27,996      0.92%     24%

----------             ----------
Earnings
per share:
Basic                $0.49                  $0.54
Assuming dilution    $0.48                  $0.53

Weighted average
common shares
outstanding:
Basic               70,628             51,967
Assuming dilution  77,613             52,770

Pro forma results excluding merger costs, costs related to facility
consolidations and employee severance and environmental remediation
included in the three months ended September 30, 2001:
Operating income      $101,265                $56,377
Net income            $47,230                $27,996
Earnings per share:
Basic                $0.67                  $0.54
Assuming dilution    $0.64                  $0.53

AmerisourceBergen Corporation
Financial Summary
(In thousands, except per share data)
Year Ended % of Year Ended % of
Sept. 30, Operating Sept. 30, Operating %
2001 Revenue 2000 Revenue Change
----------  ----------  ----------  ----------
Revenue:
Operating revenue       15,822,635 100.00% $11,609,995 100.00% 36%
Bulk deliveries
to customer
warehouses           368,718     35,026
----------            ----------
Total revenue          16,191,353 11,645,021
Cost of goods
sold                15,491,235 11,125,440 39%
----------            ----------
Gross profit           700,118   4.42%     519,581   4.48%  35%
Operating
expenses:
Distribution, selling and administrative 397,848 2.51% 302,470 2.61% 32%
Depreciation and amortization 21,589 0.14% 16,109 0.14% 34%
Facility consolidations and employee severance 10,912 0.07% (1,123) -0.01% N/A
Merger costs 13,109 0.08% - 0.00% -
Environmental remediation (2,716) -0.02% - 0.00% -

Operating income 259,376 1.64% 202,125 1.74% 28%
Equity in losses of affiliates and other 10,866 0.07% 568 0.00% N/A
Interest expense 45,677 0.29% 41,857 0.36% 9%

Income before taxes and distributions on preferred securities of subsidiary trust 202,833 1.28% 159,700 1.38% 27%
Taxes on income 77,731 0.49% 60,686 0.52% 28%

Income before distributions on preferred securities of subsidiary trust 125,102 0.79% 99,014 0.85% 26%
Distributions on preferred securities of subsidiary trust, net of income tax benefit of $871 1,306 0.01% - 0.00% -

Net income $123,796 0.78% $99,014 0.85% 25%

Earnings per share:
Basic $2.16 $1.92
Assuming dilution $2.10 $1.90

Weighted average common shares outstanding:
Basic 57,185 51,552
Assuming dilution 62,807 52,020

Pro forma results excluding merger costs, costs related to facility consolidations and employee severance and environmental remediation included in the years ended September 30, 2001 and 2000, respectively:
Operating income $280,681 $201,002
Net income $137,003 $98,318
Earnings per share:
Basic $2.40 $1.91
Assuming dilution $2.31 $1.89
### AMERISOURCEBERGEN CORPORATION

#### CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>September 30, 2001</th>
<th>September 30, 2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$297,626</td>
<td>$120,818</td>
<td>$176,808</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>2,127,663</td>
<td>623,961</td>
<td>1,503,702</td>
</tr>
<tr>
<td>Merchandise inventories</td>
<td>5,056,257</td>
<td>1,570,504</td>
<td>3,485,753</td>
</tr>
<tr>
<td>Prepaid expenses and other</td>
<td>15,956</td>
<td>5,336</td>
<td>10,620</td>
</tr>
<tr>
<td>Total current assets</td>
<td>7,497,502</td>
<td>2,320,619</td>
<td>5,176,883</td>
</tr>
<tr>
<td>Long-term assets</td>
<td>2,752,178</td>
<td>137,948</td>
<td>2,614,230</td>
</tr>
<tr>
<td>Total assets</td>
<td>$10,249,680</td>
<td>$2,458,567</td>
<td>$7,791,113</td>
</tr>
</tbody>
</table>

#### LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
- Accounts payable | $4,991,884 | $1,584,133 | $3,407,751 |
- Other current liabilities | 532,739 | 167,336 | 365,403 |
| Total current liabilities | 5,524,623 | 1,751,469 | 3,773,154 |
- Long-term debt, less current portion | 1,582,295 | 413,217 | 1,169,078 |
- Other liabilities | 29,582 | 11,587 | 17,995 |
- Company-obligated manditorily redeemable preferred securities of subsidiary trust | 274,616 | -- | 274,616 |
- Stockholders' equity | 2,838,564 | 282,294 | 2,556,270 |
| Total liabilities and stockholders' equity | $10,249,680 | $2,458,567 | $7,791,113 |

#### AMERISOURCE HEALTH CORPORATION

#### EARNINGS PER SHARE

(In thousands, except per share data)

(Earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Earnings per share-assuming dilution is computed on the basis of the weighted average number of shares of common stock outstanding during the period plus the dilutive effect of stock options. Additionally, the fiscal 2001 calculations consider the convertible subordinated notes as if converted and, therefore, the effect of interest expense related to those notes is added back to net income in determining income available to common stockholders.)

#### Three months ended Year ended

<table>
<thead>
<tr>
<th>September 30, 2001</th>
<th>September 30, 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income</td>
<td>$34,583</td>
</tr>
<tr>
<td>Interest expense</td>
<td>-</td>
</tr>
</tbody>
</table>
convertible subordinated notes, net of income tax $2,513 -- $8,112 --

Income available to common stockholders $37,096 $27,996 $131,908 $99,014

Weighted average number of shares of common stock outstanding 70,628 51,967 57,185 51,552

Effect of dilutive securities:
Stock options 1,321 803 1,076 468
Convertible subordinated notes 5,664 -- 4,546 --

Weighted average number of shares of common stock and dilutive potential common stock 77,613 52,770 62,807 52,020

Earnings per share
Basic $0.49 $0.54 $2.16 $1.92
Assuming dilution $0.48 $0.53 $2.10 $1.90

AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)

Three Months Ended September 30,

<table>
<thead>
<tr>
<th>%</th>
<th>Operating Revenue</th>
<th>2001</th>
<th>2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Distribution</td>
<td>$5,463,754</td>
<td>$3,027,776</td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>PharMerica</td>
<td>116,719</td>
<td>--</td>
<td>N/M</td>
<td></td>
</tr>
<tr>
<td>Intersegment Eliminations</td>
<td>(64,126)</td>
<td>--</td>
<td>N/M</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$5,516,347</td>
<td>$3,027,776</td>
<td>82%</td>
<td></td>
</tr>
</tbody>
</table>

Year Ended September 30,

<table>
<thead>
<tr>
<th>%</th>
<th>Operating Revenue</th>
<th>2001</th>
<th>2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Distribution</td>
<td>$15,770,042</td>
<td>$11,609,995</td>
<td>36%</td>
<td></td>
</tr>
<tr>
<td>PharMerica</td>
<td>116,719</td>
<td>--</td>
<td>N/M</td>
<td></td>
</tr>
<tr>
<td>Intersegment Eliminations</td>
<td>(64,126)</td>
<td>--</td>
<td>N/M</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$15,822,635</td>
<td>$11,609,995</td>
<td>36%</td>
<td></td>
</tr>
</tbody>
</table>

Three Months Ended September 30,

<table>
<thead>
<tr>
<th>%</th>
<th>Operating Income(a)</th>
<th>2001</th>
<th>2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Distribution</td>
<td>$94,793</td>
<td>$56,377</td>
<td>68%</td>
<td></td>
</tr>
</tbody>
</table>
## Operating Income

<table>
<thead>
<tr>
<th></th>
<th>2001</th>
<th>2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>PharMerica</td>
<td>6,472</td>
<td>N/M</td>
<td>N/M</td>
</tr>
<tr>
<td>Operating income</td>
<td>$ 101,265</td>
<td>$ 56,377</td>
<td>80%</td>
</tr>
</tbody>
</table>

### Percentages of operating revenue (a):

**Pharmaceutical Distribution**
- Gross profit: 4.15% 4.58%
- Operating expenses: 2.42% 2.72%
- Operating income: 1.73% 1.86%

**PharMerica**
- Gross profit: 34.06% --
- Operating expenses: 28.51% --
- Operating income: 5.55% --

**AmerisourceBergen Corporation**
- Gross profit: 4.83% 4.58%
- Operating expenses: 3.00% 2.72%
- Operating income: 1.84% 1.86%

(a) Before special items

### Year Ended September 30,

<table>
<thead>
<tr>
<th></th>
<th>2001</th>
<th>2000</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>PharMerica</td>
<td>6,472</td>
<td>N/M</td>
<td>N/M</td>
</tr>
<tr>
<td>Operating income</td>
<td>$ 280,681</td>
<td>$ 201,002</td>
<td>40%</td>
</tr>
</tbody>
</table>

### Percentages of operating revenue (a):

**Pharmaceutical Distribution**
- Gross profit: 4.19% 4.48%
- Operating expenses: 2.45% 2.74%
- Operating income: 1.74% 1.73%

**PharMerica**
- Gross profit: 34.06% --
- Operating expenses: 28.51% --
- Operating income: 5.55% --

**AmerisourceBergen Corporation**
- Gross profit: 4.42% 4.48%
- Operating expenses: 2.65% 2.74%
- Operating income: 1.77% 1.73%

(a) Before special items

### CONTACT:
AmerisourceBergen, Valley Forge
Michael N. Kilpatrick, 610/727-7118
mkilpatrick@amerisource.com